Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Indivior files another lawsuit in latest bid to stop copycats of its best-selling addiction drug

The UK pharma is once again back in court as it looks to prevent generic competition for its Suboxone herion addiction treatment, Indivior’s cash cow
Suboxone accounts for around 80% of Indivior’s annual revenues

Indivior PLC (LON:INDV) has filed another lawsuit against several generic drugs makers as it looks to protect its top money-making product from copycat competition.

The UK pharma company, which was spun off from Reckitt Benckiser at the end of 2014, is the maker of Suboxone, one of the best-selling treatments for heroin addiction.

READ: £1bn wiped from Indivior's market cap after US legal setback

It has previously gone down the legal route to protect its prized asset – which accounts for around four-fifths of total sales – with mixed success.

Last June, the firm won a ruling at a federal court in Delaware that meant generic versions of Suboxone won’t be allowed to hit the US market until 2024.

That was only for copycats using a certain formulation though, and Indivior was dealt a huge blow a few months later when US lawmakers ruled that a heroin addiction treatment being made by US giant Dr Reddy’s didn’t infringe on any of Indivior’s patents.

Thursday’s lawsuit has been filed against Teva, Alvogen, Par and Actavis, as well as Dr Reddy’s, all of whom have been involved in litigation with Indivior before.

The FTSE 250 group claims that all of those firms’ proposed Suboxone copycat drugs infringe a patent which was granted by the US Food and Drug Administration only last month.

READ: US states sue Indivior

“We continue to partner with Aquestive Therapeutics to innovate and generate new intellectual property around SUBOXONE Film,” said chief executive Shaun Thaxter.

“We believe this new patent is strong and we are asserting it in order to protect our intellectual property rights.”

Shares rose 0.7% to 401.3p early on Thursday.

View full INDV profile View Profile

Indivior Timeline

Related Articles

September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use